StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on MRNS. Royal Bank of Canada decreased their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Up 15.1 %

MRNS stock opened at $0.37 on Friday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $11.26. The firm has a market cap of $20.50 million, a PE ratio of -0.15 and a beta of 1.25. The business’s 50-day moving average price is $0.39 and its two-hundred day moving average price is $1.08.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the second quarter worth about $28,000. AQR Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $64,000. Hussman Strategic Advisors Inc. lifted its holdings in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares during the last quarter. Finally, World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals during the third quarter worth $104,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.